Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Galvano

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Expert Opinion on Biological Therapy|August 4, 2015
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Plos One|April 28, 2015
Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trialsAlessandro Battaggia, Alberto Donzelli, Maria Font, et al.
Oncotarget|January 6, 2017
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapyGemma Bruera, Antonio Russo, Antonio Galvano, et al.
Frontiers in Oncology|April 1, 2022
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and HealthcareNicola Silvestris, Oronzo Brunetti, Antonio Galvano, et al.
Journal of Bone Oncology|August 4, 2020
Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)Antonio Galvano, Dalila Scaturro, Viviana Bazan, et al.
Frontiers in Oncology|May 12, 2020
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?Oronzo Brunetti, Afshin Derakhshani, Behzad Baradaran, et al.
Critical Reviews in Oncology/Hematology|January 19, 2016
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2020
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung CancerValerio Gristina, Maria La Mantia, Federica Iacono, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 19, 2025
Expanding the Clinical Profile of Mild Autonomous Cortisol Secretion: New Diagnostic Markers and Emerging ComplicationsAntonio Prinzi, Ausilia Maria Lombardo, Salvatore Finocchiaro, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Expert Opinion on Biological Therapy|August 4, 2015
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, et al.
Plos One|April 28, 2015
Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trialsAlessandro Battaggia, Alberto Donzelli, Maria Font, et al.
Oncotarget|January 6, 2017
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapyGemma Bruera, Antonio Russo, Antonio Galvano, et al.
Frontiers in Oncology|April 1, 2022
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and HealthcareNicola Silvestris, Oronzo Brunetti, Antonio Galvano, et al.
Journal of Bone Oncology|August 4, 2020
Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)Antonio Galvano, Dalila Scaturro, Viviana Bazan, et al.
Frontiers in Oncology|May 12, 2020
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?Oronzo Brunetti, Afshin Derakhshani, Behzad Baradaran, et al.
Critical Reviews in Oncology/Hematology|January 19, 2016
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2020
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung CancerValerio Gristina, Maria La Mantia, Federica Iacono, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 19, 2025
Expanding the Clinical Profile of Mild Autonomous Cortisol Secretion: New Diagnostic Markers and Emerging ComplicationsAntonio Prinzi, Ausilia Maria Lombardo, Salvatore Finocchiaro, et al.
Pageof 10